AETLF yields 9523.81% · PFE yields 6.13%● Live data
📍 AETLF pulled ahead of the other in Year 1
Combined, AETLF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AETLF + PFE for your $10,000?
Aeris Environmental Ltd, together with its subsidiaries, engages in the research, development, and commercialization of proprietary technologies in Australia and internationally. The company offers heating, ventilation, air-conditioning, and refrigeration (HVAC/R) hygiene and remediation technology, indoor air quality, and corrosion protection services, as well as distributes HVAC/R hygiene, anti-corrosion, and disinfectant products. It also provides building/industrial, corporate/retail, corrosion protection, flood remediation, government/education, health/aged care, home/residential, HVAC and R, manufacturing/equipment, mould and odour control, specialty, surface cleaning and disinfection, and surface hygiene products, as well as accessories. In addition, the company offers indoor air quality assessments, mould investigations and sampling, in-house nonviable microscopy analysis, mould remediation management, post remediation verification and occupational clearance, building water ingress assessments and rectification, duct cleaning and AHU servicing management, and infection control and containment services. It provides its solutions to manufacturing and equipment, building and industrial, health and aged care, government and education, corporates and retail, and home and residential customers. The company was incorporated in 2000 and is based in Rosebery, Australia.
Full AETLF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.